Australia markets closed

EGRX Mar 2023 60.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.43000.0000 (0.00%)
As of 08:43AM EST. Market open.
Full screen
Previous close1.4300
Open1.4300
Bid0.5000
Ask1.2500
Strike60.00
Expiry date2023-03-17
Day's range1.3600 - 1.9800
Contract rangeN/A
Volume23
Open interest580
  • GlobeNewswire

    Eagle Pharmaceuticals Provides Business Update and Guidance for 2023

    WOODCLIFF LAKE, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and guidance for 2023. Highlights: During the 12 months ended September 30, 2022, Eagle recorded net income of $21.3 million or $1.63 per diluted share and adjusted EBITDA of $125.6 million and non-GAAP earnings per diluted share of $7.54, a significant increase from 2021.1Eagle exited 2022 with an approximate 6%2 share of the commercial s

  • Zacks

    Should Value Investors Buy Eagle Pharmaceuticals (EGRX) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • GlobeNewswire

    Eagle Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

    WOODCLIFF LAKE, N.J., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference as follows: Date:Tuesday, January 10, 2023Time:10:30AM PT/1:30PM ETWebcast:Click Here The webcast of the presentation will be accessible for 30 days thereafter, via the Company’s website at www.eagleus.co